The BioMed X Institute
A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
RIDGEFIELD, CT / ACCESSWIRE / June 5, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.
The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. "Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues."
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut."
"We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases," said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. "In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules," said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.
"We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research," says Mark Johnston, CEO of BioMed X USA.
About BioMed X and XSeed Labs
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds -- academia and industry -- and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model - called XSeed Labs - entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27
Related Images
SOURCE: BioMed X Institute & XSeed Labs
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Cleverbridge Appoints Markus Scheuermann as Chief Financial Officer12.2.2025 05:00:00 CET | Press release
Seasoned Finance Leader Brings 20+ Years of Expertise in Financial Strategy, M&A and Digital Transformation to Cleverbridge COLOGNE, GERMANY & CHICAGO, IL / ACCESS Newswire / February 12, 2025 / Cleverbridge, a leading provider of ecommerce and billing solutions for global software and SaaS companies, today announced the appointment of Markus Scheuermann as Chief Financial Officer, effective as of April 1, 2025.Markus Scheuermann Scheuermann is a seasoned senior executive with over 20 years of experience in financial strategy, business development, M&A, and digital transformation within high-performing technology organizations. Most recently, he served as Chief Financial Officer at Thinkproject Group and has previously held key leadership roles at HolidayCheck Group, Hubert Burda Media, eBay, and McKinsey & Company. Markus will report directly to Wendi Sturgis, Cleverbridge CEO, and be part of an executive leadership team that includes CRO Kevin Feagan, CTO Radu Immenroth, and CHRO Ale
CGFNS International Reports Nurse Migration Rates to the U.S. Remained High in 202411.2.2025 11:45:00 CET | Press release
Uncertain outlook for 2025 as new immigration policies are implemented PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 11, 2025 / A new CGFNS International report indicates that a robust annual rate of nurse migration into the United States held steady in 2024 as healthcare systems continued to look to foreign-educated nurses to help address persistent staffing shortages.CGFNS International 2024 Nurse Migration Report However, in its 2024 Nurse Migration Report, the organization also said the current high rates were likely unsustainable amid persisting visa retrogression and caps on employment-based green cards for nurses, along with new immigration policies being implemented by the Trump Administration that will likely have further impact on visa availability and processing times. CGFNS, a global health workforce non-profit that verifies credentials of healthcare professionals for immigration authorities and state licensing boards, reported that in fiscal year 2024 it received
An Incredible KLAS Triple-Award Win for AGFA HealthCare!10.2.2025 09:00:00 CET | Press release
MORTSEL, BE / ACCESS Newswire / February 10, 2025 / AGFA HealthCare proudly celebrates a remarkable KLAS triple-win, securing two #1 Best in KLAS Awards for XERO® Viewer and VNA, alongside the KLAS Most Improved Software Product for 2025. "To receive a KLAS Award is one of the most notable wins for AGFA HealthCare, and a testament to the hard work we invest into our flagship platform. More importantly, it reflects the trust and recognition from our customers. Their success is our success, and to receive two such awards is simply breathtaking." - Nathalie McCaughley, President, AGFA HealthCare The Best in KLAS report recognizes software and service providers who excel in supporting healthcare professionals and patient care. Based on extensive customer feedback and evaluations, these awards highlight AGFA HealthCare's unwavering commitment to innovation and excellence. For 2025, AGFA HealthCare's Enterprise Imaging XERO® Viewer leads the Universal Viewer (Imaging) category for the second
Eviva Partners, a New Nonprofit Promoting Better Understanding of Medical Evidence, Exposes Role of Andrew Wakefield in the “Manufacture of Evidence” Leading Up to Robert F. Kennedy Jr’s Confirmation Hearings10.2.2025 07:50:00 CET | Press release
Introduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2025 / Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through "evidence fluency" - a new framework for understanding and communicating medical evidence. "The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence," said Alex Morozov, CEO and Founder. "An investigation over the past several days reveals a role of Andrew Wakefield in the "Manufacture of Evidence" leading up to Robert F. Kennedy Jr's Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. His
Registration Now Open for World of Coffee 2025 in Geneva: The Premier Event for Coffee Professionals6.2.2025 09:00:00 CET | Press release
Join Over 13,000 Attendees and 430+ Exhibitors at Europe's Largest Specialty Coffee Trade Show GENEVA, SWITZERLAND / ACCESS Newswire / February 6, 2025 / World of Coffee, the essential event for coffee professionals, enthusiasts, and innovators from around the globe will have a 2025 edition in Geneva, Switzerland, at the Palexpo SA, June 26-28. Following the record-breaking success of World of Coffee in Copenhagen, this flagship coffee trade show is set to welcome over 13,000 coffee professionals from 160+ countries for three days of business, networking, and education. Produced by the Specialty Coffee Association (SCA), the trade show and conference are proudly supported by Host Sponsor BTW Water + More; Platinum Sponsor Barista Attitude; Diamond Sponsor Nestlé Professional; and Gold Sponsor Alpro. Café de Colombia will be featured as the Portrait Country with unique cultural activations, and a pop-up café experience. "Geneva is the ideal location for hosting our flagship European tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom